LEADING HIV PHYSICIAN, Dr. DAVID HARDY, TO DISCUSS CLINICAL USE OF THE
TROFILE(TM) ASSAY AND SELZENTRY(TM) IN CONJUNCTION WITH THE THIRD QUARTER
2008 FINANCIAL RESULTS CONFERENCE CALL
SOUTH SAN FRANCISCO, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Monogram
Biosciences, Inc., (Nasdaq: MGRM) announced that it will hold a conference
call on Monday, October 27, 2008 at 4:30 p.m. (Eastern Time) to discuss the
clinical use of Monogram's Trofile(TM) Assay in conjunction with Pfizer's
CCR5 antagonist, Selzentry(TM). Monogram will also review its third quarter
2008 financial results. The call will be hosted by William D. Young,
Chairman & CEO of Monogram. Dr. David Hardy will participate in the call.
Dr. Hardy is Director, Division of Infectious Diseases at Cedars-Sinai
Medical Center and is Associate Professor of Medicine-in-Residence at the
David Geffen School of Medicine at UCLA.
To participate in the live teleconference, please call (877) 604-9672,
or (719) 325-4896 for international callers, fifteen minutes before the
conference begins. Live audio of the call will be simultaneously broadcast
over the Internet and will be available to members of the news media,
investors and the general public. Access to live and archived audio of the
conference call will be available on the Investor Relations section at
http://www.monogrambio.com. Following the live broadcast, a replay of the
call will also be available at (888) 203-1112 or (719) 457-0820 for
international callers, through Sunday, November 9, 2008. The replay
passcode is 4461917. The information provided on the teleconference is only
accurate at the time of the conference call, and Monogram will take no
responsibility for providing updated information except as required by law.
About Monogram Biosciences, Inc.
Monogram is advancing individualized medicine by discovering,
developing and marketing innovative products to guide and improve treatment
of serious infectious diseases and cancer. The Company's products are
designed to help doctors optimize treatment regimens for their patients
that lead to better outcomes and reduced costs. The Company's technology is
also being used by numerous biopharmaceutical companies to develop new and
improved anti-viral therapeutics and vaccines as well as targeted cancer
therapeutics. More information about the Company and its technology can be
found on its web site at http://www.monogrambio.com.
Trofile is a trademark of Monogram Biosciences, Inc. Selzentry is a
trademark of Pfizer Inc.
contacts: Alfred G. Merriweather Jeremiah Hall
Chief Financial Officer Feinstein Kean Healthcare
Tel: 650 624-4576 Tel: 415 677-2700
amerriweather@monogrambio.com jeremiah.hall@fkhealth.com
SOURCE Monogram Biosciences, Inc.
 back to top
Related links:
http://www.monogrambio.com
CONTACT:
Alfred G. Merriweather, Chief Financial
Officer of Monogram Biosciences, Inc., +1-650-624-4576,
amerriweather@monogrambio.com; or Jeremiah Hall of Feinstein Kean
Healthcare for Monogram Biosciences, Inc., +1-415-677- 2700,
jeremiah.hall@fkhealth.com
|
